×

Achaogen Announces Webcast Providing Update on Development Plan for Plazomicin

SOUTH SAN FRANCISCO, Calif., March 30, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, is pleased to host a webcast and teleconference providing an update on its lead program, plazomicin. The webcast and teleconference will take place on Tuesday, March 31st at 4:30PM Eastern Time where management will review its updated development plan for the program.

To access the live webcast, please visit the Investor Relations page of Achaogen at http://investors.achaogen.com/. Alternatively, participants may access the live conference call by dialing (855) 757-8872 (US) or (262) 912-6174 (international) and using conference ID 15387796. A replay of the webcast will be available on Achaogen's website for at least 30 days following the call.

About Plazomicin

Plazomicin is a novel aminoglycoside antibiotic designed to treat serious gram-negative infections. It has shown potent bactericidal activity in nonclinical studies against important gram-negative pathogens, including CRE. Plazomicin is currently being evaluated in a Phase 3 CARE (Combating Antibiotic Resistant Enterobacteriaceae) trial for the treatment of bacteremia and nosocomial pneumonia caused by CRE, which is one of the top global threats in infectious disease due to high rates of mortality in infected patients. In 2013, the CDC labeled CRE as "nightmare bacteria" and indicated that CRE poses a public health threat requiring "urgent and aggressive action."

About Achaogen

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE. Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections.

CONTACT: Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 105 cknoll@bplifescience.com

Source:Achaogen Inc.